PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Naltrexone with bupropion - Weight management in adults
PAD Profile : Naltrexone with bupropion - Weight management in adults
Keywords :
weight loss, obesity, overweight
Brand Names Include :
Mysimba
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
No indications returned.
Additional Documents
Type
Document
Review Date
Committee Recommendations
Date
Committee Name
Narrative
22 January 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network does not recommend the use of Naltrexone-bupropion for managing overweight and obesity. This is in line with NICE TA494.
Naltrexone-bupropion will be considered BLACK on the traffic light status for all new patients.
This recommendation is not intended to affect treatment with naltrexone–bupropion that was started in the NHS before this guidance was published. Adults having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Associated BNF Codes
04. Central Nervous System
04.05.01. Gastro-intestinal anti-obesity drugs